Rokhsare Zareie
1, Mahsa Asadollahi Hamedani
2 
, Reyhaneh Sadeghian
2 , Yaser Khanchemehr
2 , Mahboubeh Belali Kharaji
2 , Elahe Zaremoghadam
3 , Negar Shahkarami
4 , Atena Samareh Fekri
5* 1 Department of Nursing, School of Nursing and Midwifery, Zahedan University of Medical Sciences, Zahedan, Iran
2 Department of Nursing, Faculty of Nursing and Midwifery, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
3 Department of Internal Medicine, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran
4 Instructor of Operating Room, School of Allied Medical Sciences, Fasa University of Medical Sciences, Fasa, Iran
5 Department of Anesthesiology, Faculty of Allied Medical Sciences, Kerman University of Medical Sciences, Kerman, Iran
Abstract
Biomarkers are molecules that can be measured in the body and can reflect disease activity or progression. They can be used to diagnose and monitor disease, predict treatment response, and identify potential therapeutic targets. Several types of biomarkers have been studied in the context of IgA nephropathy, including protein, gene expression, epigenetic, and microRNA biomarkers. Biomarkers have the potential to improve the accuracy and specificity of the diagnosis of IgA nephropathy and predict the disease progression and response to treatment. However, further studies are needed to validate their diagnostic value in larger cohorts of patients and to integrate them into clinical practice. The development of multi-omics approaches that combine different types of biomarkers may provide a more comprehensive understanding of the disease pathogenesis and potential treatments.